NCT01610167

Brief Summary

The study is intended to verify through clinical measurement that the NUPRO Sensodyne Prophylaxis Paste with Novamin provides immediate sensitivity relief as well as extended relief up to 28 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
151

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2011

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 30, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 1, 2012

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

October 14, 2013

Completed
Last Updated

October 14, 2013

Status Verified

August 1, 2013

Enrollment Period

3 months

First QC Date

May 30, 2012

Results QC Date

February 20, 2013

Last Update Submit

August 8, 2013

Conditions

Outcome Measures

Primary Outcomes (3)

  • Immediate Sensitivity Relief. Tactile Sensitivity.

    Assessment of sensitivity via tactile stimulation immediately after treatment. Tactile sensitivity measured using a Yeaple probe recording tactile pressure in grams before nerve stimulation. Point of nerve stimulation identified by patient with a "yes" response as pressure is increased in 10 gram increments. Tactile sensitivity is reported as the change from baseline after treatment.

    Immediately after treatment.

  • Adverse Events.

    Assessment of adverse events that may occur as a result of treatment (typically includes any kind of allergic reation to paste).

    Immediately after treatment to 28 days (+/- 2 days) post treatment.

  • Immediate Sensitivity Relief. Air Blast Sensitivity.

    Sensitivity measurements performed using a cold air blast and sensitivity scored on the four (4) point Schiff scale with 0 equal to no discomfort or awareness of sensitivity and 3 equal to severe pain from sensitive teeth. Score is reported as the change from baseline after treatment.

    Immediately after treatment.

Secondary Outcomes (2)

  • Extended Sensitivity Relief. Tactile Sensitivity.

    28 days (+/- 2 days) post treatment.

  • Extended Sensitivity Relief. Air Blast Sensitivity.

    28 days (+/- 2 days) post treatment.

Study Arms (3)

NUPRO(r) Classic Prophy Paste

ACTIVE COMPARATOR
Device: NUPRO Classic Prophy Paste

NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.

EXPERIMENTAL
Device: NUPRO Sensodyne Prophy Paste with Novamin with fluoride.

NUPRO Sensodyne Prophy Paste w/ Novamin

EXPERIMENTAL
Device: NUPRO Sensodyne Prophy Paste with Novamin without fluoride.

Interventions

Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.

NUPRO(r) Classic Prophy Paste

Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.

NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.

Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.

NUPRO Sensodyne Prophy Paste w/ Novamin

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Availability to complete in the 28 day duration of the study.
  • Two sensitive teeth which are not adjacent to each other and preferably in different quadrants and demonstrate cervical erosion, abrasion, and gingival recession.
  • qualifying response to tactile stimuli as defined by a score of \</= 20 grams.
  • Qualifying response to air blast stimuli as defined by a score of \>/= 1 on the Schiff Cold Air Sensitivity Scale.
  • Good general health with no known allergies to products being tested.
  • Use of a non-desensitizing dentifrice for 3 weeks prior to entry into the study.
  • Able to follow study procedures and instructions.
  • Must have a minimum of 10 natural evaluable teeth, excluding 3rd molars.

You may not qualify if:

  • Individuals who exhibit gross oral pathology
  • Females who may be pregnant or lactating or intending to become pregnant
  • Individuals who require anesthetic during scaling
  • Dental pathology which may cause pain similar to tooth sensitivity
  • Individuals with large amounts of calculus
  • Subjects with active infectious diseases such as hepatitis, HIV or tuberculosis
  • Any condition requiring antibiotic prophylaxis for dental treatment
  • Excessive gingival inflammation
  • Individuals who had their teeth cleaned within 30 days of the screening appointment
  • Individuals who have had a desensitizing treatment or tooth bleaching within 90 days of screening appointment.
  • Oral pathology, chronic disease, or history of allergy to test products
  • Advanced periodontal disease or treatment for periodontal disease (including surgery) within the past twelve months.
  • Sensitive teeth with mobility greater than one.
  • Teeth with extensive/defective restorations (including prosthetic crowns), suspected pulpitis, caries, cracked enamel, or used as abutments for removable partial dentures.
  • Regular use of sedatives, anti-inflammatory drugs, or analgesic
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Salus Research

Fort Wayne, Indiana, 46825, United States

Location

MeSH Terms

Conditions

Dentin Sensitivity

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic Diseases

Results Point of Contact

Title
Jeffery L. Milleman, DDS, MPA
Organization
Salus Research, Inc.

Study Officials

  • Jeffery L. Milleman, DDS, MPA

    Salus Research

    PRINCIPAL INVESTIGATOR
  • Kimberly R. Milleman, ASDH, MS

    Salus Research

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2012

First Posted

June 1, 2012

Study Start

September 1, 2011

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

October 14, 2013

Results First Posted

October 14, 2013

Record last verified: 2013-08

Locations